OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Xifeng Wu on Prognostic Factor of Obesity-Related Genes in RCC

May 4th 2016

Xifeng Wu, MD, PhD, chair, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, director, Center for Translational and Public Health Genomics, professor, The University of Texas MD Anderson Cancer Center, discusses the prognostic factor of obesity-related genes in patients with renal cell carcinoma (RCC).

Leonie de Best on Validation of EMC92/SKY92 Signature in Myeloma

May 4th 2016

Leonie de Best, MSc2, chief operating officer, SkylineDX, discusses the HOVON-87/NMSG-18 study, which demonstrated the validation of the EMC92/SKY92 signature for elderly patients with newly diagnosed multiple myeloma.

Patricia Goldsmith on Financial Stress Associated With Cancer Care

May 3rd 2016

Patricia J. Goldsmith, chief executive officer, CancerCare, previews data of a CancerCare study highlighting some of the financial challenges associated with patients who have cancer.

Fred Schumacher on Genetic Risk Factors of Prostate Cancer

May 3rd 2016

Fred Schumacher, PhD, MPH, associate professor, Case Western Reserve University, discusses a study that led to the identification of genetic risk factors of prostate cancer.

Wendy Setiawan on Pancreatic Cancer Incidence Across Ethnic Populations

May 2nd 2016

Wendy Setiawan, PhD, assistant professor of Preventive Medicine, Department of Preventive Medicine, Keck School of Medicine of University of Southern California, discusses a study that examined differences in pancreatic cancer incidence across five racial/ethnic populations in a multiethnic cohort.

Dr. Van Morris on Nivolumab as a Potential Treatment for Patients With Anal Cancer

May 2nd 2016

Van K. Morris, MD, assistant professor of GI Oncology, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) as a potential treatment for patients with anal cancer.

Thomas Dubensky on How ADU-S100 Activates STING

April 29th 2016

Thomas W. Dubensky Jr, PhD, chief scientific officer, Aduro Biotech, discusses a study of ADU-S100 and how it activates the human STING receptor, which is found to have presence in multiple tumor types.

Dr. Ribas on Triplet Regimens in Melanoma

April 29th 2016

Antoni Ribas, MD, PhD, professor of Hematology and Oncology and director of the Tumor Immunology Program Area at UCLA Jonsson Comprehensive Cancer Center, discusses triplet therapies for patients with melanoma and the sequencing challenges associated with the approvals of additional agents in the field.

Dr. Partridge on PGD in Young Patients With Breast Cancer

April 28th 2016

Ann H. Partridge, MD, MPH, founder and director, Program for Young Women with Breast Cancer, director, Adult Survivorship Program, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses preimplantation genetic diagnosis (PGD) in young patients with breast cancer.

Dr. Rubin on Advantages With Whole-Exome Sequencing

April 28th 2016

Mark A. Rubin, MD, professor of Pathology and Laboratory Medicine, vice chairman for Experimental Pathology, director, Translational Research Laboratory Services, Weill Cornell Medicine and New-York Presbyterian, discusses the advantages of whole-exome sequencing and how it compares with targeted sequencing.

Dr. Demetri on the Evolving Field of Sarcoma

April 27th 2016

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the evolving and advancing field of sarcoma.

Meredith Buxton on I-SPY 2 Trial for HER2+ Breast Cancer

April 26th 2016

Meredith Buxton, PhD, research director, assistant professor, University of California, San Francisco School of Medicine, discusses the I-SPY 2 trial for patients with HER2-positive breast cancer.

Dr. Choueiri on FDA Approval of Cabozantinib for RCC

April 26th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, comments on the FDA approval of cabozantinib as a second-line treatment of patients with renal cell carcinoma (RCC).

Dr. Stock on the Optimal Use of Radium-223 in mCRPC

April 25th 2016

Richard G. Stock, MD, senior faculty, Radiation Oncology, Mount Sinai Hospital, discusses the optimal use of radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Kelly on the JAVELIN Solid Tumor Trial

April 22nd 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of the phase Ib JAVELIN Solid Tumor Trial.

Dr. Stephen Grubbs on Measuring Value in Oncology

April 21st 2016

Stephen S. Grubbs, MD, senior director of the new clinical affairs department of the American Society of Clinical Oncology (ASCO) discusses value-based oncology.

Sangeetha Palakurthi on Strategies for Managing Resistance to Osimertinib in Patients With NSCLC

April 21st 2016

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized nonâ€“small cell lung cancer (NSCLC) patient-derived xenografts from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.

Dr. Spencer on Radiation Therapy for Patients With Head and Neck Cancer

April 14th 2016

Sharon Spencer, MD, professor, chief of Medical Services, Ruby Meredith Outstanding Clinician Endowed Chair, University of Alabama at Birmingham School of Medicine, discusses the types of radiation therapy available to patients with head and neck cancer.

Dr. Udit Verma on Regorafenib in Patients With mCRC

April 13th 2016

Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer.

Dr. Levy on Impact of Nivolumab, Pembrolizumab Approvals in NSCLC

April 12th 2016

Benjamin P. Levy, MD, assistant professor of Medicine, Hematology, and Medical Oncology at Mount Sinai Hospital, discusses how nivolumab (Opdivo) and pembrolizumab (Keytruda) have impacted the treatment landscape of nonâ€“small cell lung cancer.